Validation of the SF-36 in Jamaicans with sickle-cell disease

Asnani, Monika; Lipps, Garth; Reid, Marvin

doi:10.1080/13548500903016567

Cited by 21 publications

(32 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possible score ranges are 27-116; 8-41; 9-45; and 10-30 for the overall score, role limitations, mental health and physical health dimensions, respectively. In previous research in Jamaicans with SCD, the Cronbach's alpha values for each subscale in the same order were 0.65, 0.86, 0.84 and 0.86 (Asnani, Lipps, & Reid, 2009b).…”

Section: Short Form 36mentioning

confidence: 94%

“…Principal components analysis of the SF-36 using data collected from persons with SCD in Jamaica has shown the clustering of items around three dimensions: "Physical Health", "Mental Health" and "Role Limitations" (Asnani, Lipps, & Reid, 2007). Possible score ranges are 27-116; 8-41; 9-45; and 10-30 for the overall score, role limitations, mental health and physical health dimensions, respectively.…”

Section: Short Form 36mentioning

confidence: 99%

See 1 more Smart Citation

Locus of control, depression and quality of life among persons with sickle cell disease in Jamaica

Gibson

Morgan

Abel

et al. 2013

Psychology, Health & Medicine

Self Cite

View full text Add to dashboard Cite

This study explored how locus of control (LOC), depression and quality of life (QOL) interplay in patients with sickle cell disease. One hundred and forty-three sickle cell clinic patients with consecutive clinic consultations completed the Multidimensional Health Locus of Control and Short Factor 36 (SF-36) scales as well as the Beck Depression Inventory. Participants in this study had higher scores on the "chance", "other people" and "internal" domains of LOC than persons with a number of other chronic illnesses in a previous study. Hierarchical regression analyses showed that high scores on the "internal" domain of LOC were associated with better QOL and fewer symptoms of depression. Depressive symptoms were greater in persons with high scores on the "other people" LOC domain and in younger persons. These findings would suggest that it is possible that interventions which enhance internal LOC and discourage "other people" orientations might improve QOL and ameliorate depression among persons with sickle cell disease.

show abstract

Section: Short Form 36mentioning

confidence: 94%

Section: Short Form 36mentioning

confidence: 99%

Locus of control, depression and quality of life among persons with sickle cell disease in Jamaica

Gibson

Morgan

Abel

et al. 2013

Psychology, Health & Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…31 In adults with SCD, HRQoL was previously assessed using the SF-36 in large clinical studies, 12,32 and it has been validated against 2 other quality-of-life measures in SCD patients. 33 The SF-36 Health Survey consists of 36 items that cover 8 sections consisting of physical functioning; role limitations due to physical health, bodily pain, general health, vitality, and social functioning; and role limitations due to emotional problems and mental health. The scores from the 8 sections are combined into 2 summary scores;…”

Section: Hrqolmentioning

confidence: 99%

Depression, quality of life, and medical resource utilization in sickle cell disease

et al. 2017

View full text Add to dashboard Cite

Key Points• Depression was found in 35.2% of adult SCD patients and was strongly associated with worse physical and mental quality-of-life outcomes.• Total health care costs for adult SCD patients with depression were more than double those of SCD patients without depression.Sickle cell disease (SCD) is a chronic, debilitating disorder. Chronically ill patients are at risk for depression, which can affect health-related quality of life (HRQoL), health care utilization, and cost. We performed an analytic epidemiologic prospective study to determine the prevalence of depression in adult patients with SCD and its association with HRQoL and medical resource utilization. Depression was measured by the Beck Depression Inventory and clinical history in adult SCD outpatients at a comprehensive SCD center. HRQoL was assessed using the SF36 form, and data were collected on medical resource utilization and corresponding cost. Neurocognitive functions were assessed using the CNS Vital Signs tool.Pain diaries were used to record daily pain. Out of 142 enrolled patients, 42 (35.2%) had depression. Depression was associated with worse physical and mental HRQoL scores (P , .0001 and P , .0001, respectively). Mean total inpatient costs ($25 000 vs $7487, P 5 .02) and total health care costs ($30 665 vs $13 016, P 5 .01) were significantly higher in patients with depression during the 12 months preceding diagnosis. Similarly, during the 6 months following diagnosis, mean total health care costs were significantly higher in depressed patients than in nondepressed patients ($13 766 vs $8670, P 5 .04). Depression is prevalent in adult patients with SCD and is associated with worse HRQoL and higher total health care costs. Efforts should focus on prevention, early diagnosis, and therapy for depression in SCD.

show abstract

“…The importance of the CHQ-PF50 and SF-36 questionnaires and the results of the individual scales on the actions that should be taken for pediatric and adult patients with SCD have been reported. 10,[16][17][18][19][20][21] However, there is little published data on HRQoL in HU-treated pediatric and adult patients with SCD. 15,[22][23][24] HU treatment benefits include reduced frequency of acute sickle cell pain and acute chest syndrome, reduced need for blood transfusions and hospitalizations, and possibly improved survival.…”

Section: Discussionmentioning

confidence: 99%

Quality of Life, Clinical Effectiveness, and Satisfaction in Pediatric and Young Adult Patients with Sickle Cell Disease Receiving Hydroxyurea Therapy

Cevher¹,

Ünal²,

Küçükkavruk³

et al. 2018

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

A AB BS ST TR RA AC CT T O Ob bj je ec ct ti iv ve e: : Despite documented benefits of hydroxyurea (HU) for pediatric and young adults with sickle cell disease (SCD), there is still limited experience with the use of HU in these age groups and knowledge regarding its long-term efficacy, safety, and acceptance remains poorly defined. This study aims to evaluate quality of life, clinical effectiveness, and satisfaction in pediatric and young adult patients with SCD receiving HU. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : In this study, 34 pediatric (7-11 and 12-17 years) and 16 young adult (18-22 years) patients with SCD receiving HU for at least a year were participated. The data for effectiveness of hydroxyurea therapy and parameters that may affect compliance to treatment and life quality of the participants were evaluated with using Demographic Data Collection Form, Life Quality Survey Short Form-36 (SF-36), Child Health Questionnaire-Parent Form 50, Case Report Form and HU Satisfaction Survey. R Re es su ul lt ts s: : The patients aged 7-11, 12-17, and 18-22 years were being treated with HU at 15.3±4.0 (for 4.7±2.7 years), 14.4±3.7 (for 5.7±3.3 years), and 14.0±6.4 mg/kg/day (for 5.1±2.6 years), respectively. Correlation studies revealed that HU dose was not significantly correlated SF-36 summary scores in these patients. Duration of HU therapy was positively correlated with the SF-36 summary scores for physical functioning, physical role limitation, mental health, and general health perception in the young adult patients. However, duration of HU therapy was negatively correlated with the perceived effectiveness of therapy while positive correlations were observed between duration of treatment and burden of therapy/side effects. C Co on nc cl lu us si io on n: : These findings suggest that the health quality and compliance of the pediatric and young adult patients to therapy might be low due to not sufficiently effective HU therapy in addition to comorbidities, concomitant drug use, and side effects. K Ke ey yw wo or rd ds s: : Hydroxyurea; anemia, sickle cell; compliance Ö ÖZ ZE ET T A Am ma aç ç: : Orak hücre hastalığı (OHH) olan pediatrik ve genç erişkin hastalarda hidroksiüre (HÜ)'nün yararlarının biliniyor olmasına karşın, bu yaş gruplarında HÜ'nün kullanımıyla ilgili deneyim hala sınırlıdır ve uzun süreli etkililiği, güvenliği ve kabul edilebilirliğine ilişkin bilgiler yetersiz kalmıştır. Bu çalışmada OHH nedeniyle HÜ tedavisi gören pediatrik ve genç erişkin hastalarda yaşam kalitesi, klinik etkinlik ve tedaviye uyum değerlendirilmiştir. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Bu çalış-maya, OHH nedeniyle en az 1 yıl süre HÜ tedavisi gören 34 pediatrik (7-11 ve 12-17 yaş) ile 16 genç erişkin (18-22 yaş) hasta katılmıştır. HÜ tedavisinin etkinliği ve katılımcıların tedaviye uyuncu ile yaşam kalitesine ilişkin veriler Demografik Veri Toplama Formu, Yaşam Kalitesi Anketi Kısa Form-36 (KF-36), Çocuk Sağlığı Anketi (Anne/Baba Raporu) 50, Olgu Rapor Formu ve HÜ Tedavisinden Memn...

show abstract

Validation of the SF-36 in Jamaicans with sickle-cell disease

Cited by 21 publications

References 30 publications

Locus of control, depression and quality of life among persons with sickle cell disease in Jamaica

Locus of control, depression and quality of life among persons with sickle cell disease in Jamaica

Depression, quality of life, and medical resource utilization in sickle cell disease

Quality of Life, Clinical Effectiveness, and Satisfaction in Pediatric and Young Adult Patients with Sickle Cell Disease Receiving Hydroxyurea Therapy

Contact Info

Product

Resources

About